$SRNE STI-8282, which Dr. Henry Ji referred to yesterday in the R&D as "Mesenchymal Stem Cell Program (MSC)" is in Phase 1 of Human Clinical Trails that started August 15, 2020. - Sorrento Therapeutics will be assuming responsibility for executing the Phase 1 trial from Personalized Stem Cells, Inc, which is targeted to enroll about 20 hospitalized COVID-19 patients in California. - Study 1st Posted on FDA website: July 24 2020 - Estimated Study Start Date: August 15 2020 - Estimated Enrollment: 20 hospitalized COVID-19 patients - Estimated Completion Date: January 15 2021 Clinical Trail Information: clinicaltrials.gov/ct2/show... SRNE Press Release: investors.sorrentotherapeut...
  • 8
8 Likes